MétaCan
Menu
Back to cohort
Record W2951994857 · doi:10.1002/hon.52_2629

FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

2019· article· en· W2951994857 on OpenAlexaff
Kirsten Fischer, M. Porro Lurà, Othman Al‐Sawaf, Jasmin Bahlo, Anna Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, K. Humphrey, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, S. Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, William Schary, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl‐Anton Kreuzer, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Matthias Ritgen, Michael Hallek

Bibliographic record

VenueHematological Oncology · 2019
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsQueen Elizabeth II Health Sciences CentreCapital District Health Authority
FundersUniversità degli Studi di PerugiaHospital de Clínicas de Porto AlegreMonash UniversityF. Hoffmann-La Roche
KeywordsMedicineInternal medicineGastroenterologyMinimal residual diseaseObinutuzumabHazard ratioClinical endpointPopulationSurrogate endpointOncologyVenetoclaxProgression-free survivalConfidence intervalSurgeryChronic lymphocytic leukemiaRandomized controlled trialBone marrowLeukemiaChemotherapy

Abstract

fetched live from OpenAlex

validated and the 3 risk groups were reproduced in 9 stage A series, including clinical trials (CLL1, n=547, c-index 0.71; CLL7, n=339, cindex 0.73; O-CLL1, n=312, c-index 0.67), institutional (MDACC, n=1225, c-index 0.66; Barcelona, n=355, c-index 0.75; Brno, n=269, c-index 0.69; Sapienza University, n=250, c-index 0.70; Southampton, n=227, c-index 0.75), and population based-series (SCAN, n=224, cindex 0.70).By compiling the training and validation series to narrow the confidence interval of the estimates, among low risk patients median TTFT was not reached and at 10 years 77% of patients were treatment free.Among intermediate-risk patients, median TTFT was 10.69 years (95% CI 9.31-13.60).Among high-risk patients, median TTFT was 3.89 years (95% CI 3.56-4.30)(Fig. 1).Conclusions: Among stage A CLL initially managed with active surveillance, the IPS-A allows to inform upfront patients, physicians and researchers about the likelihood of disease progression.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.276
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207